Biotech will support development of a new treatment for multiple sclerosis
CLEVELAND, OH, September 26, 2018 — Sujana Biotech, a biotechnology company developing novel therapeutics to prevent inflammatory and vascular disorders, today announced new funding from the award of a Phase I Small Business Innovation Research (SBIR) grant from the National Institute of Neurological Disorders and Stroke at the National Institutes for Health. The funding from this $219,029 grant will support the development of a monoclonal antibody for the treatment of multiple sclerosis (MS).
MS is a rare, chronic inflammatory disease of the central nervous system than affects more than 2.3 million people worldwide. Current treatments relieve the symptoms but do not cure the disease. Sujana’s goal is to develop an antibody that prevents the interaction between platelets and white blood cells, providing greater medical benefit and fewer side effects than the medicines currently available for the millions of patients living with MS.
In addition to MS, Sujana is investigating efficacy of its antibody in several other inflammatory and vascular diseases.
Sujana was launched by BioMotiv, the accelerator associated with The Harrington Project for Discovery & Development. The company’s technologies are licensed exclusively from Case Western Reserve University School of Medicine and University Hospitals Cleveland Medical Center, with collaborations at the Cleveland Clinic Foundation. The technology is based on discoveries of Drs. Daniel Simon, Edward Plow, and Yunmei Wang. Sujana has received two prior grant awards from the National Institutes of Health for developing its technologies.
About Sujana Biotech
Sujana Biotech is a start-up biotechnology company developing novel therapeutics to prevent inflammatory and vascular disorders. The company’s technology is based on discoveries developed at University Hospitals Cleveland Medical Center, Case Western Reserve University and the Cleveland Clinic Foundation. Learn more at www.sujanabio.com.
BioMotiv is the mission-driven accelerator associated with The Harrington Project for Discovery & Development, a $340 million initiative for advancing medicine centered at University Hospitals in Cleveland. The focus is to accelerate breakthrough discoveries from research institutions into therapeutics for patients through an innovative model that efficiently aligns capital and collaborations. The company leverages an experienced team and advisory board to select, fund, and actively manage and advance a portfolio of drug development programs. Learn more at: www.biomotiv.com.